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1. Introduction  
 
1.1. The ACMD reviewed etizolam and a group of previously uncontrolled 
benzodiazepines in December 2016, prompted by concerns of the abuse 
potential of etizolam and its involvement in several deaths across the UK 
[ACMD, 2016a]. That report recommended that etizolam and 15 other 
previously uncontrolled benzodiazepines (listed in Annex A) should be 
controlled under Class C of the Misuse of Drugs Act 1971 (MDA) and placed 
under Schedule 1 of the Misuse of Drugs Regulations 2001 (MDR) [ACMD, 
2016b]. These controls came into force in May 2017. 
 
1.2. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
collates information about novel psychoactive substances identified from 
participating countries in seizures, test purchasing and forensic testing, and 
records this information on the European Database on New Drugs (EDND). 
Since the publication of the ACMD (2016) report there have been notifications 
of 9 benzodiazepines detected in seizures across Europe and reported to the 
EMCDDA, and the ACMD have identified a further 4 benzodiazepines listed 
on the EDND. These 13 benzodiazepines are not currently classified under 
the MDA. Although some of these compounds were originally developed as 
medicines in the 1960s and 1970s and some are currently licensed medicines 
in other countries, they are considered to be novel psychoactive substances 
in the context of drug misuse.  
 
1.3. This report examines the UK prevalence and available evidence of harm of 
these 13 benzodiazepines and makes recommendations about inclusion of 
some of these substances in the MDA and MDR. For the purposes of this 
report, the term novel benzodiazepines refers to this list of 13 substances.  
 
1.4. Limited information is available about the health and social harms of newly 
emerging benzodiazepines, although in view of their closely related chemical 
structure and pharmacology, these are likely to be similar to those of other 
established benzodiazepines. Some of the newer versions are highly potent 
with the potential of producing harm at low dose. This report therefore 
includes a summary of the evidence of health and social harms associated 
with benzodiazepine misuse in general. 
2. Legal control of benzodiazepines  
2.1. In the UK, benzodiazepines licensed as medicines are largely controlled as 
Class C drugs under the MDA and listed in Schedule 4 Part 1 of the MDR. 
Temazepam, flunitrazepam and midazolam are regulated under Schedule 3 of 
the MDR because of their misuse potential and increased risk of diversion. 
Benzodiazepines that are not licensed as medicines have been controlled as 
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Class C drugs and are listed in either Schedule 1 (no recognised medicinal 
use in the UK) or Schedule 4 part 1 of the MDR as detailed in Annex A. 
 
2.2. Benzodiazepines that are not currently classified under the MDA are likely to 
be captured by the Psychoactive Substances Act 2016 (PSA). 
Benzodiazepines that are licensed as medicines internationally but not in the 
UK may be regarded as medicinal products for the purpose of the ‘medicinal 
products’ exemption to the PSA. For this exemption to apply, the product must 
meet the definition of medicinal product in Regulation 2 of the Human 
Medicines Regulations 2012. The Medicines and Healthcare products 
Regulatory Agency (MHRA), which is an executive agency of the Department 
of Health and Social Care (DHSC), decides what satisfies the definition of a 
medicinal product for the purposes of the 2012 Regulations. 
 
2.3. In the UK, benzodiazepines are controlled under the MDA by the listing of 
individual substances – rather than by the use of a generic definition. The 
ACMD believe this remains an appropriate model of control as the analogue 
variation of benzodiazepines is proportionally low compared to other drugs 
groups such as synthetic cannabinoids or fentanyls. As a result of the 
infrequent rate with which illicit use of benzodiazepines is displaced to novel 
analogues, substances that become problematic can be addressed 
individually. Germany has developed a generic control for benzodiazepines 
[Federal Republic of Germany, 2019] due to concerns regarding a significant 
increase in seizures of ‘designer’ benzodiazepines across Europe in 2016. Of 
particular concern was the extreme potency of some of these new 
compounds. For example, flubromazolam (one of the 16 benzodiazepines that 
were controlled in the UK in 2017) is effective at doses well below 1 mg.  
 
2.4. The German generic definition was designed to ensure all established and 
novel analogues of this drug group were brought within the scope of their 
Narcotics Act. Their generic definition is based on the use of a series of 
structural diagrams of 16 different benzodiazepine cores, together with a 
defined range of modifications, coupled with a limit on the molecular weight of 
the materials controlled. This allows control of specific benzodiazepine sub-
groups (i.e. 1,4-benzodiazepines, 1,5-benzodiazepines, loprazolam 
derivatives, etc.) while limiting control to the small, pharmacologically active, 
analogues. It would be challenging to implement this type of expansive 
generic definition within UK legislation, where only descriptive text is used and 
the clarity of the definition would be lost in rendering the many core structural 
diagrams into text. Instead, the UK can utilise legislation such as the PSA - 
which prohibits the manufacture and supply of all psychoactive substances - 
to enable general benzodiazepine control. For this reason, the approach of 
utilising a generic definition is not recommended by the ACMD to encompass 
benzodiazepines under the MDA.  
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2.5. At the international level, the World Health Organization’s Expert Committee 
on Drug Dependence (WHO ECDD) continues to review particular emerging 
compounds of concern. At their 42nd meeting in October 2019 [WHO 2019b], 
WHO ECDD recommended that flualprazolam (currently not classified under 
the MDA or scheduled under the MDR, but considered in this report) and 
etizolam (currently Class C of the MDA and Schedule 1 or the MDR) should 
be brought under international control by the addition of these compounds to 
Schedule IV of the 1971 Convention on Psychotropic Substances. The United 
Nations Commission on Narcotic Drugs (CND) voted in favour of the WHO 
ECDD recommendation at their 63rd Session held in March 2020. As a result, 
both substances have now been added to Schedule IV of the 1971 
Convention on Psychotropic Substances, where the benzodiazepines 
alprazolam and triazolam are currently also scheduled [CND, 2020]. 
3. Benzodiazepine chemistry and pharmacology  
3.1. Benzodiazepines are sedative and anxiolytic drugs that have been in clinical 
use since the 1960s for the treatment of anxiety, insomnia, muscle spasms, 
spasticity and epilepsy. They are also used as premedication for anaesthesia 
and as adjuncts for withdrawal from alcohol and other substances [Farias et 
al, 2017; Hayhoe & Lee-Davey, 2018; Moosmann & Auwärter, 2018]. 
Commonly prescribed benzodiazepines include diazepam, temazepam, 
chlordiazepoxide and lorazepam - but there are many other benzodiazepines 
licensed as medicines in the UK (Annex A) and further examples are licensed 
in other countries (e.g. etizolam, phenazepam).   
 
3.2. Benzodiazepines work as central nervous system depressants by enhancing 
the actions of gamma-aminobutyric acid (GABA), the major inhibitory 
neurotransmitter in the brain and spinal cord. This neurotransmitter has an 
inhibitory (‘calming’) effect on many functions of the brain, inducing sedation 
and sleep [EMCDDA, 2018]. The (GABA)-A receptor, a ligand-gated chloride-
selective ion channel, modulates the action of GABA. Benzodiazepines act as 
positive allosteric modulators to the (GABA)-A receptor, meaning they bind to 
the receptor to amplify any effects [Griffin et al, 2013]. 
 
3.3. In the brain there are multiple types of GABA-A receptors, made up from 
different combinations of protein subunits and benzodiazepines can vary in 
pharmacological effect depending on the type of GABA-A receptors they 
interact with. Sedation and sleep induction result primarily from interactions 
with GABA-A receptors containing the α1 subunit [McKernan et al, 2000]. The 
anxiolytic effects appear to be mediated through the α2 and α3 subunit-
containing receptors [Atack, 2010], whilst interaction with the α5 subunit may 
contribute to improvement of mood and cognition [Jacob, 2019]. 
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3.4. The diversity in chemical structures of benzodiazepines affects their lipid 
solubility, and this affects how they are handled in the body, including the 
duration of their psychoactive effects. [EMCDDA, 2018]. Benzodiazepines can 
be categorised as: 
 
• short-acting agents, with half-lives of less than 6 hours (e.g. midazolam, 
triazolam); 
• intermediate-acting agents, with half-lives of 6 to 24 hours (e.g. 
temazepam, alprazolam); 
• long-acting agents, with half-lives of over 24 hours (e.g. diazepam).  
 
3.5. Adverse effects of benzodiazepines include drowsiness, psychomotor 
impairment, unsteadiness and incoordination, memory loss and confusion. 
Higher doses may cause loss of consciousness and respiratory depression, 
especially if used in combination with alcohol or other sedatives [White & 
Irvine, 1999; CDC, 2014]. Toxicity arising from overdose or use in 
combination with other central nervous system depressants is a relatively 
frequent Emergency Department presentation [EMCDDA, 2018]. Death 
arising from the use of benzodiazepines is thought to be uncommon in 
otherwise healthy people, unless other drugs or alcohol have also been used. 
Data provided by the National Programme on Substance Abuse Deaths 
(NPSAD) showed that in England between 2006 and 2015 there were 5740 
benzodiazepine related deaths. Of these 5740 deaths, 207 (3.6%) recorded 
benzodiazepines as the only compounds implicated in the cause of death.  
 
3.6. Benzodiazepine use is common in people who use opioids, such as heroin, 
and this combination is particularly hazardous, with each drug exacerbating 
the respiratory depression caused by the other, resulting in an increased risk 
of death. There is a reversal agent for benzodiazepine toxicity, flumazenil, 
which acts as a competitive antagonist at the benzodiazepine-binding site on 
the GABA-A receptor. Use of this can improve consciousness level but may 
precipitate seizures, especially if drugs that lower seizure threshold have also 
been taken [Seger, 2004; An & Godwin, 2016]. 
4. Benzodiazepine misuse  
4.1. Medicinal use of benzodiazepines became popular by the mid-1970s, but 
evidence subsequently emerged of benzodiazepine tolerance and 
dependence and the development of severe withdrawal symptoms after use 
for more than a few weeks [Hayhoe & Lee-Davey, 2018; PHE, 2019a]. 
Subsequently, the potential for benzodiazepine misuse became increasingly 
recognised [Moosmann & Auwärter, 2018]. 
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4.2. Benzodiazepines can be misused in a variety of ways, often in the context of 
polydrug use [Schmitz, 2016]. They may be used with other sedatives to 
potentiate their effects, or they may be used to ‘come down’ after stimulant 
use. They are also sometimes used by injection to produce heroin-like effects, 
and benzodiazepines such as alprazolam (‘Xanax’) are sometimes found 
mixed into heroin as ‘extenders’.   
 
4.3. In the past, misuse has arisen from diversion of medicinal benzodiazepines 
[Hayhoe & Lee-Davey, 2018], but synthetic processes for benzodiazepine 
manufacture are now freely available, and many illicitly manufactured 
benzodiazepines have been encountered in recent years [Moosmann et al, 
2015]. These can evade local (national) drug misuse legislation, at least 
initially, and can often be bought in bulk, usually via the internet. 
 
4.4. Prescribing of benzodiazepines by General Practitioners in the UK has been 
discouraged and has fallen progressively in recent years. Prescription items 
issued in primary care in England fell from 16.3 million in 2015-16 to 14.9 
million in 2018-19 [NHSBA, 2020]. Following their launch, there was 
increased prescribing of the related so-called ‘Z-drugs’ (zopiclone, zolpidem 
and zaleplon) [Hayhoe & Lee-Davey, 2018] but this started to reverse in 2014. 
In 2017-18, there were 1.4 million adults in England and Wales who received 
one or more benzodiazepine prescriptions. Of those prescribed a 
benzodiazepine in 2015, 5% received this continuously for at least 12 months 
and 120,000 people received continuous benzodiazepine prescribing between 
April 2015 and March 2018. Long-term benzodiazepine use was associated 
with low income and the use of benzodiazepines that are short-acting agents 
[PHE, 2019a].   
 
4.5. In contrast to the prescribing data, deaths where a benzodiazepine was 
implicated have increased over the past decade across the UK (Figure 1), 
consistent with an increased role of illicitly manufactured benzodiazepines. 
There is evidence of this in Scotland, where ‘street’ or unlicensed 
benzodiazepines were involved in 85% of the 792 deaths in 2018 where a 
benzodiazepine was implicated, while medicinal ‘prescribed’ benzodiazepines 
were reported in only 30% [NRS, 2019]. 
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4.6. Benzodiazepine misuse is more common in those with underlying medical or 
psychiatric conditions (including anxiety, panic disorder or agoraphobia, 
chronic sleep disorder, co-morbid psychiatric disorders and substance use 
disorders [Guina & Merrill, 2018]), and people with lower educational or socio-
economic status are also at increased risk of misuse. A systematic review in 
the US found that women were more likely to display stronger associations 
between psychiatric distress and benzodiazepine misuse [Votaw et al, 2019]. 
 
4.7. Younger adults (18-29 years) [Kurtz, 2011; 2017] often source and misuse 
legally prescribed benzodiazepines and may also purchase illegally obtained 
benzodiazepines and their analogues. The under-18 substance misuse 
treatment statistics for England in 2018-19 demonstrated a 53% increase in 
young people reporting a problem with benzodiazepines than reported in 
2017-18 and a 3-fold increase against what was reported in 2016-17 [PHE, 
2019b]. A recent study found that young people who obtained 
benzodiazepines from multiple sources, legal and illegal, were also more 
likely to have a substance use disorder [McCabe et al., 2018]. 
 
Benzodiazepine use with opioids  
 
4.8. Individuals with concomitant opioid disorders report using benzodiazepines to 
enhance the effects of the opioid-based drug and this in turn is a strong 
predictor of a more severe polysubstance use problem (including more 
harmful patterns of use of benzodiazepines) [Vogel et al, 2013]. 
Figure 1: Number of Benzodiazepine-related deaths by year of death registration for England 
and Wales [ONS, 2019], Northern Ireland [NISRA, 2020] and Scotland [NRS, 2019]. The ONS and 
NISRA definition of benzodiazepine-related death refers to death where any benzodiazepine was 
mentioned on the death certificate. The NRS definition of Benzodiazepine-related death covers 
deaths which any benzodiazepine was implicated in, or which potentially contributed to the 
cause of death. 
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Benzodiazepines may also be used to combat the effects of opioid withdrawal 
[Stein et al, 2016; Vogel et al, 2013]. Overdoses associated with the ingestion 
of benzodiazepines are more likely to occur with concomitant use of opioids. 
Results from two studies which considered overdose in people with opioid use 
disorders and injecting use highlighted that benzodiazepine use was 
associated with higher rates of mortality, including overdose deaths [Pavarin, 
2015; Riley et al, 2016]. An increased risk of mortality has also been identified 
in patients with concurrent opioid and benzodiazepine prescriptions [Sun et al, 
2017]. Furthermore, patients taking a combination of prescribed opioids and 
benzodiazepines were found to take higher opioid doses and for longer 
periods [Kay et al, 2019]. 
 
Social harms of benzodiazepine use  
 
4.9. Social harms and harms to others associated with benzodiazepine use 
include criminal activity, aggression and violence, risk-taking behaviours, 
suicide ideation/attempts and concurrent substance use disorders. 
 
4.10. Benzodiazepines can cause paradoxical reactions such as disinhibition, 
excitement, irritability, hostility and violence, arguments and inappropriate 
sexual behaviour. Whilst all benzodiazepines have the propensity to cause 
aggressive behavioural reactions, there is evidence that alprazolam is of 
particular concern [Jones et al, 2011; Albrecht et al, 2014]. Several studies 
have found that individuals who use alcohol and alprazolam can show 
increased signs of aggression and anger compared to those who use the 
substances individually. Whilst the drugs may induce increased feelings of 
relaxation, they also decrease an individual’s ability to regulate their feelings 
and behaviour and may increase impulsivity. However, this may depend on 
the proportions of alcohol and drug ingested. Three of the novel 
benzodiazepines considered in more detail in this report (flualprazolam, 
flunitrazolam and clobromazolam) are structurally related to alprazolam. 
 
4.11. Criminal activity associated with benzodiazepine usage includes offences 
against the person, sexual offences and burglary, and the risk is increased for 
highly potent substances. Qualitative studies have highlighted that some 
perpetrators reported that using benzodiazepines lowered their inhibitions and 
increased their self-confidence prior to the committing of offences. Supply of 
such materials from illicit manufacturing facilities may also lead to 
unpredictable dosages and unintended overdosing [Votaw et al, 2019].  
 
4.12. In a Norwegian study, which considered blood concentrations of ‘designer’ 
benzodiazepines in a population of drugged drivers and other offenders, blood 
results indicated the presence of one or more designer benzodiazepines 
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(clonazolam, diclazepam, flubromazepam, flubromazolam or pyrazolam) in 77 
cases over 3 years [Høiseth et al, 2016]. 
 
Suicide 
 
4.13. There is a strong correlation between benzodiazepine use and suicide 
ideation in general populations [Schepis et al, 2018b] and sub-populations, for 
example adolescents [Juan et al, 2015] and those with alcohol dependence 
[Presuss et al, 2003] or opioid use disorders [Wines et al, 2004; Backmund et 
al, 2011]. Analysis of US general population data demonstrated that those 
with concomitant misuse of a benzodiazepine with another drug reported a 
higher rate of suicide ideation than reported for those with singular drug 
misuse problems [Schepis et al, 2018a].  Benzodiazepine intoxication, high-
dose prescription of benzodiazepines and a diagnosis of depression are also 
considered significant risk factors in reported and completed suicides. 
5. Prevalence and harm summaries of Novel 
Benzodiazepines 
 
This section summarises the available evidence on pharmacology, 
identifications in the UK and reported evidence of harm for 13 
benzodiazepines that have been notified to the EMCDDA but are currently not 
classified under the MDA.  
The majority of these novel benzodiazepines are likely to have commensurate 
harms to benzodiazepines controlled under the MDA, as many are structurally 
related to previously controlled benzodiazepines. Most changes in the 
chemical structure involve either the substitution of a halogen atom with a 
different halogen or the addition of an extra halogen atom. In this text, 
substances in italics are benzodiazepines that are already controlled as Class 
C compounds under the MDA (listed also in Annex A). The chemical 
structures of the novel benzodiazepines discussed in this section are shown 
in Annex B, alongside the chemical structures of some examples of 
benzodiazepines that are already controlled via the MDA. 
A consultation with the MHRA confirmed that there are no legitimate medicinal 
uses in the UK for any of these 13 substances. 
1. Flualprazolam 
IUPAC: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine 
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Flualprazolam (also known as Ro 11-5073/000, 2’-fluoro alprazolam, ortho-
fluoro alprazolam or ‘flualp’) is a 1,2,4-triazolobenzodiazepine, where the 
diazepine ring is fused to a triazole ring. It is the 2-fluoro derivative of the 
benzodiazepine alprazolam. It is also structurally related to triazolam, differing 
by the replacement of the chlorine with fluorine at the 2-position (ortho 
position) on the phenyl ring, which is attached to the benzodiazepine moiety. 
It is also similar in structure to flubromazolam, which was brought under Class 
C control of the MDA in 2017.   
Flualprazolam was patented in 1970 but was never marketed as a medicine. 
Methods of manufacture have been published [Fustero et al, 2006; WHO, 
2019a].  No specific information is available on how the drug is handled by the 
body (pharmacokinetics), but properties are likely to be similar to those of 
alprazolam, which has a half-life of 9.5–12 hours [Garzone & Kroboth, 1989]. 
The onset of action of flualprazolam is reported to be 10–30 minutes after oral 
use, with a duration of action of 6–14 hours [Zawilska & Wojcieszak, 2019]. 
There is limited pharmacological information available about flualprazolam, 
but a study of triazolobenzodiazepines reported that substitution of chlorine or 
fluorine at the ortho position of the phenyl ring attached to the benzodiazepine 
moiety in a series of alprazolam-related substances, produced compounds 
with dramatically enhanced activity [Hester et al, 1971]. In pharmacological 
tests conducted on mice, flualprazolam was reported to be active at doses of 
less than 10 μg/kg [Orsolini et al, 2020].  
As of March 2020, no studies of animal or human abuse or dependency 
potential have been published. Typical doses used in humans are in the range 
of 0.125 mg to 2.5 mg. Online user fora suggest similar effects from 
flualprazolam as those associated with clonazepam and alprazolam. These 
effects are consistent with preclinical studies described in the patent 
application demonstrating sedative/tranquilizer and muscle relaxant effects 
[WHO, 2019a].  
Involvement of flualprazolam in the drug misuse markets was first notified to 
the EMCDDA EU Early Warning System by Sweden in November 2017, 
following a police seizure of a powder. Sales of the substance in powder form 
have been reported, advertised as flualprazolam. The EMCDDA issued a 
report on flualprazolam in March 2019, which noted that flualprazolam had 
been detected in Denmark, Finland, Germany, Slovenia, Sweden and 
Norway. More than 30,000 flualprazolam tablets were seized during 2018. 
Seizures reported by Sweden provided evidence that flualprazolam had been 
used to make falsified (fake) ‘Xanax’ and ‘Xanor’ tablets. 
In this March 2019 report EMCDDA detailed deaths with confirmed exposure 
to flualprazolam have been reported by Sweden (24 deaths) and Finland (2 
deaths). The cause of death was reported in 15 of these cases; in 8 of these 
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flualprazolam was cited as a contributing or possible contributing factor. 
Where additional toxicology information was available, other substances were 
detected in all cases. 
There have been 42 flualprazolam reports on the United Nations Office of 
Drugs and Crime (UNODC) Early Warning Advisory on NPS Toxicology Portal 
(Tox-Portal), 40 from the US as well as 2 from Finland (which may be the 
same 2 cases reported to the EMCDDA). Five of these cases were post-
mortem, 21 ante-mortem and the remainder were not classified. 
Flualprazolam was considered causal to the event in 5 cases. There has also 
been a case report published from China describing the use of flualprazolam 
to sedate a victim for the purposes of robbery [Qian et al, 2020]. 
In the UK, several identifications of the compound have been reported from 
seizures and samples analysed by National Crime Agency (NCA), TICTAC 
Communications Ltd. and Welsh Emerging Drug & Identification of Novel 
Substances (WEDINOS) (see Annex C), as well as anecdotal reports of use 
from clients in receipt of treatment from Postscript360, a Bristol-based charity 
providing treatment solutions and referral pathways for people with 
benzodiazepine dependence. This indicates significant availability of this 
compound in UK markets. Of tablets sold as diazepam or alprazolam, 
analysis by WEDINOS has demonstrated the proportions containing 
flualprazolam to be 13% and 15%, respectively. The National Institute for 
Health Research (NIHR)-funded Identification of Novel Psychoactive 
Substances (IONA) study has analysed samples from 853 people attending a 
hospital with toxicity related to drug misuse since 2015. Although 
benzodiazepines were commonly detected (e.g. diazepam or a metabolite 
identified in 302 people), the only novel benzodiazepine identified so far has 
been flualprazolam, identified in 5 people between June 2019 and February 
2020. 
 
As of March 2020, there have been 12 flualprazolam-associated deaths in the 
UK recorded by regional statistical agencies (see Annex D). In October 2019, 
an unknown number of deaths were reported in Stockton-on-Tees where 
flualprazolam was the only psychoactive substance present. 
 
2. Norfludiazepam  
IUPAC name: 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-
one 
Norfludiazepam (also known as norflurazepam, desalkylflurazepam or Ro 05-
3367) is structurally related to diazepam and 4-chlorodiazepam and can be 
used in the synthesis of midazolam. It is also a pharmacologically active 
metabolite of several other benzodiazepines including midazolam, flurazepam 
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and fludiazepam [Orsolini et al, 2020]. Norfludiazepam is a more potent 
inhibitor of 3H-flunitrazepam cerebellar or hypocampal membrane binding 
than diazepam [Sieghart, 1983]. It has a long elimination half-life (74 ± 24 
hours) compared to flurazepam (2 hours) and has been shown to accumulate 
during prolonged administration of midazolam. 
Norfludiazepam has been notified in the UK from a police seizure of 14 pale-
blue tablets in March 2017 and one sample analysis by TICTAC in December 
2017. Small-scale seizures of a mixture of tablets and powders have also 
been notified in Germany (2016), Sweden (2017), Norway (2018), and 
Denmark (2019).  
Clients in receipt of treatment for benzodiazepine dependency via 
Postscript360 have also anecdotally reported either the use or purchase of 
norfludiazepam.  
No deaths related to norfludiazepam have been reported in the UK as of 
March 2020. 
 
3. Flunitrazolam 
IUPAC name: 6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine 
Flunitrazolam is a triazolo benzodiazepine structurally related to clonazolam 
(clonitrazolam), differing by the substitution of 2-chloro with 2-fluoro on the 
phenyl group. It is also the triazolo version of flunitrazepam. It was first 
discovered in the 1960s but has not yet been marketed as a pharmaceutical 
in any country [Cornett et al, 2018]. As such, there is limited information about 
doses, effects, safety and tolerability available. However, based on its 
structural similarity to other triazolo-benzodiazepines, it is likely that the 
potency of flunitrazolam is greater than of the already highly potent 
flunitrazepam [Orsolini et al, 2020]. Peak concentrations (178 pg/ml) were 
achieved in oral fluid 3 hours after ingestion of a 0.25 mg tablet of 
flunitrazolam by a single male volunteer [Ameline et al, 2019].  
A small number of detections of flunitrazolam, branded as ‘Rohypnol’ (the 
proprietary name for flunitrazepam), were seized at the UK border between 
2014 and October 2019 (detailed in Annex C). One case of flunitrazolam 
detection was reported by the NCA in late 2018. Flunitrazolam has also been 
notified in Sweden (2016) from a police seizure of tablets. Small-scale 
seizures of a mixture of tablets and powder have also been notified in 
Germany (2016) and Denmark (2017). 
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As of March 2020, no deaths or other harms associated with flunitrazolam 
have been reported in the UK. However, the specialist benzodiazepine 
charity, Postscript360, have reported that clients in receipt of treatment for 
benzodiazepine dependency had anecdotally reported either the use or 
purchase of flunitrazolam.  
 
4. Methyl clonazepam 
IUPAC: 5-(2-chlorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one 
Methyl clonazepam (also known as ID 690, Ro 05-4082) is a 1,4-
benzodiazepine originally developed as a pharmaceutical in the 1970s. 
Although shown to have anxiolytic properties similar to those of lorazepam 
[Ansseau et al, 1985], it has never been licensed as a medicine. Methyl 
clonazepam is structurally related to flunitrazepam, differing by the 
substitution of the fluorine with a chlorine atom. It also shares structural 
similarities with diclazepam and cloniprazepam. In vivo studies in rats 
demonstrated that methyl clonazepam is equal in potency to nitrazepam and 
clonazepam, and is more potent than diazepam for muscle relaxant and 
anticonvulsant action (all of which are classified under Class C of the MDA) 
[Fukuda et al, 1977].  
Methyl clonazepam was first notified in Sweden in December 2017, in a 
border seizure of powder. As of March 2020, it has not been detected in drug 
seizures or associated with deaths in the UK. The specialist benzodiazepine 
charity, Postscript360, have reported that clients in receipt of treatment for 
benzodiazepine dependency had reported anecdotally either the use or 
purchase of methyl clonazepam.  
 
5. Cloniprazepam  
IUPAC name: 5-(2-chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-
2H-1,4-benzodiazepin-2-one 
Cloniprazepam (also known as Kloniprazepam and 1-Cyclopropylmethyl 
clonazepam) is a 1,4-benzodiazepine structurally similar to clonazolam 
(clonitrazolam) and meclonazepam and described as a pro-drug for 
clonazepam [Mortelé et al, 2018]. It is a more potent inhibitor of 3H-
flunitrazepam cerebellar or hypocampal membrane binding than diazepam 
[Sieghart, 1983]. Doses may range from 0.5 to 4 mg but are typically 1–2 mg 
[Mooseman & Auwärter, 2018]. Symptoms occur 15–45 minutes after 
ingestion, with clinical effects lasting 6–9 hours [Orsolini et al, 2020]. 
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The compound was first notified in January 2016 in Sweden, from a police 
seizure of capsules. Sales of the substance have been reported online as 
packs of 20, 60, 120 and 240 capsules of 2.5 mg strength.  
Data up to November 2019 shows that cloniprazepam has not been detected 
in UK Border Force or NCA seizures. There have been no telephone 
enquiries to the National Poisons Information Service (NPIS) and only 24 
accesses to the relevant information on TOXBASE since 2016. No deaths or 
other harms have been recorded in the UK as of March 2020. 
 
6. Difludiazepam  
IUPAC: 7-chloro-5-(2,6-difluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one 
Also known as Ro 07-4065, difludiazepam is structurally related to diazepam 
and fludiazepam, differing by the addition of fluoro substituents in both the 2- 
and 6-positions (just the 6-position in the case of fludiazepam). It is also 
structurally related to norfludiazepam (considered above, not currently 
classified under the MDA) differing by the addition of a fluoro substituent in 
the 6-position on the phenyl ring and the addition of a methyl group attached 
to the amide. Although a new substance to be identified in illicit drug markets, 
it was originally described in a 1972 patent, and has been used in research to 
determine the shape and function of the GABA receptor complex [Orsolini et 
al, 2020].  
This compound was first notified in Sweden, May 2017, following a border 
seizure of a power originating from China. Seizures made by law enforcement 
in Sweden have been labelled as ‘sample for research’. 
As of March 2020, difludiazepam has not been detected in drug seizures and 
no deaths or other harms have been recorded in the UK. 
 
7. Thionordazepam 
IUPAC: 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione 
Thionordazepam (also known as thionordiazepam), is structurally related to 
nordazepam and diazepam and can be used in the synthesis of alprazolam. 
No pharmacological information is currently available. 
This compound was first notified in Sweden in June 2017, following a border 
seizure of powder.  
As of March 2020, this compound has not been detected in drug seizures in 
the UK and no deaths or other harms have been recorded in the UK. 
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8. Fluclotizolam 
IUPAC: 2-chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepine 
Originally mentioned in a patent from 1974, fluclotizolam is a thienodiazepine, 
where the diazepine ring is fused to a thiophene instead of a benzene ring. It 
is structurally related to brotizolam and etizolam, differing by the substituents 
at the thiophene and phenyl ring. Based on its similarity to brotizolam and 
etizolam, the substance is expected to have sedative hypnotic effects. There 
are conflicting anecdotal reports on doses used, though claims have been 
made that it has an approximately 3-fold higher potency and a shorter half-life 
compared to etizolam [Orsolini et al, 2020].  
This compound was first notified in Sweden, October 2017, in a police seizure 
of tablets. It was notified in the same month in Denmark, in a border seizure of 
blotters originating from the Netherlands. As of March 2020 it has not been 
detected in drug seizures or associated with deaths or other harms in the UK. 
 
9. Tofisopam 
IUPAC: 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-
benzodiazepine 
Unlike many of the classical 1,4-benzodiazepines under international control, 
tofisopam is a 2,3-benzodiazepine. The 1,4- and 2,3-benzodiazepines differ in 
the position of the nitrogen atoms in the diazepine ring. As a result, the 
compound contains a stereogenic centre and exists as a pair of enantiomers.  
Tofisopam is authorised as a pharmaceutical in some European countries 
under the name Grandaxin. It is also known as tofizopam, Emandaxin, EGYT 
341, Nodeprine, Seriel and TF. It is administered orally at a dose of 300 mg 
daily for the treatment of neurosis and somatic disorders associated with 
tension, anxiety, vegetative disorders, lack of energy and motivation, apathy, 
fatigue, depressed mood and alcohol withdrawal syndrome [Orsolini et al, 
2020].  
Unlike typical 1,4-benzodiazepines the literature suggests that tofisopam does 
not act on the GABA-A receptor but enhances the binding of other 
benzodiazepines to their binding sites [Petócz, 1993]. It has anxiolytic activity 
with reduced sedative and muscle relaxant side-effects in humans. Under 
some circumstances it has stimulant properties, although sedation may occur 
after high doses and tofisopam may enhance the effects of barbiturates and 
ethanol [Petócz, 1993]. The lack of action on the GABA-A receptor raises the 
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possibility that sedative effects may not be reduced by the benzodiazepine 
antidote flumazenil. Tofisopam is rapidly absorbed from the intestinal tract but 
undergoes extensive first-pass hepatic metabolism; peak plasma 
concentrations are reached within 1–1.5 hours. The major pathway for the 
metabolic transformation of tofisopam is demethylation and its elimination 
half-life is 6–8 hours.  
Tofisopam was first notified in Europe in November 2017, following a border 
seizure of tablets in Sweden. It has not been detected in drug seizures or 
associated with deaths or other harms in the UK as of March 2020. 
 
10. Clobromazolam 
IUPAC: 8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine 
Clobromazolam (sometimes called Phenazolam) is the 2-chloro derivative of 
bromazolam and shares structural similarities with clonazolam and 
flubromazolam, respectively. Clobromazolam is also structurally related to 
phenazepam, alprazolam and triazolam. It differs from triazolam due to the 
replacement of chlorine with bromine at the 8-position on the benzodiazepine 
moiety. Oral administration in mice resulted in central nervous system 
depression, ataxia and convulsive reactions at doses of 0.2–1 g/kg, with 
symptoms lasting more than 24 hours [Polívka et al, 1983].  
 
Clobromazolam was first notified in Sweden in March 2016, from a police 
seizure of capsules. From data up to March 2020, there is no evidence of 
prevalence or health harms associated with clobromazolam in the UK. 
 
11. Cinazepam 
IUPAC: 4-[[7-bromo-5-(2-chlorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-
3-yl]oxy]-4-oxo-butanoic acid 
Cinazepam (also known as BD-798) is structurally related to benzodiazepines 
phenazepam and 3-hydroxyphenazepam. It appears to have high-potency 
binding (in the nanomolar range) to the GABA-A receptor [Makan et al, 2007]. 
Cinazepam has been used in medical manufacturing in the Ukraine and has 
recently been included in the patent of a novel therapy for treating anxiety 
disorders, epilepsy, and pain. It is reported to produce hypnotic and anxiolytic 
effects and relatively weak sedative and muscle relaxant effects and to be 
more potent than phenazepam. In vivo it is substantially converted to the 
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active metabolite 3-hydroxyphenazepam. The median elimination half-life of 
cinazepam was reported as 16–23 hours.  
 
Cinazepam was first notified in Norway in March 2016, in a border force 
seizure of tablets. There is no direct evidence of prevalence or health harms 
associated with this compound in the UK, from data up to March 2020. 
Numbers of accesses to the cinazepam information on TOXBASE have 
increased from 4 in 2017 to 56 in the first quarter of 2019. It is not known if 
these accesses relate directly to the management of patients with exposure to 
cinazepam or have been made for other reasons. 
 
12. Bentazepam 
IUPAC: 5-phenyl-1,3,6,7,8,9-hexahydro-2H-[1]benzothieno[2,3-
e][1,4]diazepin-2-one  
Bentazepam (also known as thiadipone or tiadipone) is a thienodiazepine, i.e. 
a benzodiazepine derivative where the diazepine ring is fused to a thiophene 
instead of benzene. This class of compounds also includes etizolam, 
metizolam, and fluclotizolam, but bentazepam differs from these three 
substances due to the presence of a cyclohexane ring fused to the thiophene 
instead of a triazole fused to the benzodiazepine.  
Bentazepam was previously used as a medicine in Spain. It is known to 
produce anxiolytic, anticonvulsant, sedative and muscle relaxant effects and 
is used for the treatment of anxiety, including when associated with social 
phobia and post-traumatic stress disorder [Honorato et al, 1990]. Dosage 
reports have indicated that a low dose is 15–30 mg and a typical dose is 30–
50 mg. Pronounced effects are experienced with doses greater than 50 mg. 
Clinical effects develop 15–45 minutes after oral intake and may last for up to 
8 hours after administration [Orsolini et al, 2020]. Unlike other 
benzodiazepines, hepatitis and severe liver damage have been associated 
with therapeutic use [De-la-Serna et al, 1997; Andrade et al, 2000; 2006] as 
well as cases of colitis [Fernández-Bañares et al, 2003]. 
The compound was first notified in Sweden in March 2014, in a police seizure 
of tablets. As of March 2020, there is no evidence of prevalence or health 
harms associated with bentazepam in the UK. 
 
13. Alprazolam triazolobenzophenone derivative  
IUPAC: [2-[3-(aminomethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-5-chlorophenyl]
phenyl-methanone 
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This compound was developed by the Upjohn Company in the 1980s as a 
water-soluble pro-drug of alprazolam intended for administration as an 
injection or infusion. It rapidly converts to alprazolam at neutral pH. Acyl 
derivatives of the primary amino group of this compound have also been 
studied as prodrugs for alprazolam [Cho et al, 1986]. 
 
The alprazolam triazolobenzophenone derivative was first notified by Spain in 
March 2014, in a border seizure of powder that had originated from India. 
There is no evidence of prevalence or health harms associated with this 
compound in the UK from data up to March 2020. 
 
6. Conclusions  
 
6.1. There is evidence from drug seizure data of prevalence for 3 of the 13 
compounds in the UK, namely flualprazolam, flunitrazolam and 
norfludiazepam. Numbers of seizures have been greatest for flualprazolam 
and this compound has also been associated with 12 deaths in the UK. 
 
6.2. For the other 10 novel benzodiazepines considered in this report, there is 
currently no analytical evidence of prevalence or health harms in the UK. All 
of these compounds have the potential to cause health harms should they 
emerge into the UK drug market. They are currently controlled via the PSA 
and this remains appropriate until further evidence of harm emerges. 
 
6.3. Whilst there are examples of some of the novel benzodiazepines being used 
as licenced medical products abroad, there is no evidence for legitimate 
medicinal uses of these substances in the UK. 
 
6.4. There is an ongoing risk in the UK that further uncontrolled novel 
benzodiazepines may appear. Continued monitoring for evidence of 
prevalence or health harms related to compounds that are not currently 
controlled via the MDA therefore remains important. Benzodiazepines that are 
not currently classified under the MDA will fall within the prevision of the PSA. 
The ACMD have previously advised [ACMD, 2019] that Temporary Class 
Drug Orders (TCDO) can be used in conjunction with the PSA as a 
mechanism to apply stricter controls for emerging compounds causing 
particular problems. By the action of a TCDO, the ACMD would have 12 
months to collect, collate and make a recommendation on the uncontrolled 
novel benzodiazepine(s) covered by that order, for potential inclusion under 
the MDA.  
 
6.5. The ACMD has considered the possibility of adopting a generic control of 
benzodiazepines based on chemical structure, similar to the German 
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legislation. This is not recommended as it is not possible within UK legislation 
where only descriptive text is used and the PSA is in place to support wider 
control of benzodiazepines.  
 
7. Recommendation 
 
The ACMD recommends that the following substances are classified under 
Class C of the Misuse of Drugs Act 1971, like other classified 
benzodiazepines, and placed under Schedule 1 of the Misuse of Drugs 
Regulations 2001 (as amended) because they have no medicinal use:  
• 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine (flualprazolam) 
• 6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine (flunitrazolam)  
• 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one 
(norfludiazepam) 
Owing to the absence of asymmetric centres or functional groups that can 
form esters or ethers, there are no structural derivatives that will need to be 
considered in this legislation for the above three compounds.   
Leads: Home Office, Drugs and Alcohol Unit 
Measure of outcome: The inclusion of the 3 compounds under Class C of 
the Misuse of Drugs Act 1971 and Schedule 1 of the Misuse of Drugs 
Regulations 2001.  
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Annex A: List of benzodiazepines controlled under the 
Misuse of Drugs Act 1971 and Misuse of Drugs 
Regulations 2001 
 
Category Licensed as medicines in 
the UK 
Not licensed as medicines in the UK 
MDA  Class C Class C Class C Class C Class C 
MDR  Schedule  
4 Pt 1 
Schedule 3 Schedule 4 
Pt 1 
Schedule 3 Schedule 1 
Examples Alprazolam 
Chlordiazepoxide 
Clobazam 
Clonazepam 
Diazepam 
Flurazepam 
Loprazolam 
Lorazepam 
Lormetazepam 
Nitrazepam 
Oxazepam 
 
 
Midazolam 
Temazepam 
 
Bromazepam 
Brotizolam 
Camazepam 
Clorazepic 
acid 
Clotiazepam 
Cloxazolam 
Delorazepam 
Estazolam 
Fludiazepam 
Halazepam 
Haloxazolam 
Ketazolam 
Medazepam 
Nimetazepam 
Nordazepam 
Oxazepam 
Oxazolam 
Pinazepam 
Prazepam 
Tetrazepam 
Triazolam 
Flunitrazepam  *Adinazolam 
*Bromazolam 
*4'-Chlorodiazepam 
*Clonazolam 
*Deschloroetizolam 
*Diclazepam 
*Etizolam 
*Flubromazepam 
*Flubromazolam 
*Fonazepam 
*3Hydroxyphenaze
pam 
*Meclonazepam 
*Metizolam 
*Nifoxipam 
*Nitrazolam 
*Pyrazolam 
 
 
 
 
 
*16 Substances that were brought under control in May 2017, MDA SI 2017/634 
and for the MDR SI 2017/631 
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Annex B: Benzodiazepine Chemical Structures  
Where the compound is one of the 13 novel benzodiazepines considered, the # 
number refers to numbered segment within section 5 of the report. 
1,4-benzodiazepines 
1,4 benzodiazepines have nitrogen atoms in the 1 and 4 position of the diazepine 
ring, which is fused to a benzene ring. Naming convention is for them to end in ‘pam’ 
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Thienodiazepine analogues of 1,4-benzodiazepines 
This is a sub-group of 1,4-benzodiazepines in which the fused benzene ring is 
replaced with a fused thiophene ring. As the thiophene ring is bound to a 1,4 
diazepine the naming convention is to end in ‘pam’ as above. 
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Triazolo 1,4-benzodiazepines 
These compounds have a triazolo ring fused to the 1,4 diazepine ring, as well as a 
benzene ring. Naming convention is for them to end in ‘lam’  
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Thienodiazepine analogues of triazolo 1,4-benzodiazepines 
This is a sub-group of triazolo 1,4-benzodiazepines in which the fused benzene ring 
is replaced with a fused thiophene ring. As the thiophene ring is bound to a triazolo 
1,4 diazepine the naming convention is to end in ‘lam’ as above.  
 
 
 
 
 
 
 
 
 
 
 
2,3-benzodiazepines 
2,3 benzodiazepines have nitrogen atoms in the 2 and 3 position of the diazepine 
ring, which is fused to a benzene ring. Naming convention is for them to end in ‘pam’ 
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Alternative structures 
Some benzodiazepine-type materials are pro-drugs (something that after 
administration, is metabolized into a pharmacologically active drug). This means that 
they have alternative structures to the above examples, but then convert to the 
benzodiazepine moiety in the body.  
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Annex C: Summary of novel benzodiazepine identifications 
in UK seizure and sampling data  
 
The use of the term ‘novel benzodiazepines’ in this section refers to the list of 13 
compounds that the ACMD has considered in this report for control under the MDA. 
UK Border Forces Seizures 
A small number of detections of flunitrazolam, branded as ‘Rohypnol’, have been 
made at the UK border between 2014 and October 2019. Note that genuine 
‘Rohypnol’ contains flunitrazepam, which is controlled in Class C of the MDA and 
Schedule 3 of the MDR.  
 
[Official sensitive paragraph has been redacted from the published version of this 
report] 
 
Forensic Early Warning System (FEWS) Novel Psychoactive Substances (NPS) 
Collection Plans 
As part of the FEWS project, the Defence Science and Technology Laboratory 
(DSTL) facilitated the collection and analysis of suspected NPS samples seized by 
UK Border Force officials at five fast parcel and postal hubs in the UK. Participating 
centres submitted samples seized between April 2018 and February 2019, however, 
there were no detections of novel benzodiazepines. Of the 149 samples received, 50 
(34%) of the samples contained an NPS, but there was only one benzodiazepine 
detected (4 detections of etizolam, already Class C under the MDA).  
In addition to the collection and analysis of suspected NPS samples seized at Border 
Force, DSTL conducted two further collection plans as part of the FEWS project.  
Vulnerable Group Collection Plan 
DSTL facilitated the collection and analysis of suspected NPS samples seized 
between March 2018 and February 2019 by police from the homeless community 
and non-attributable samples found on the premises at three Immigration Removal 
Centres. Of the 109 samples received, (98% of which were provided by the 
participating Immigration Removal Centres) there was only one benzodiazepine 
detected, diclazepam, which is already controlled by the MDA. No detections of 
novel benzodiazepines were found in this sample set.  
Prison Collection Plan 
DSTL facilitated the collection and analysis of suspected NPS in non-attributable 
samples recovered from 14 participating prison grounds between March 2018 and 
February 2019. In the 432 samples received there were no benzodiazepines 
detected.   
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National Crime Agency (NCA) Seizures   
The NCA is a government sponsored agency employed to combat serious and 
organised crime, working with partners to develop, deploy and maintain specialist 
capabilities and services that are delivered nationally. They collate information from 
forensic providers on seizures submitted for forensic examination in England and 
Wales. In the period from January 2017 to June 2019, the NCA reported the 
appearance of 2 novel benzodiazepines, flualprazolam and flunitrazolam. No further 
novel benzodiazepines have been forensically identified in seizures for the time 
period January 2017 to June 2019.   
 2017 2018 2019  
Drug Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Total  
Flualprazolam         3 14 17 
Flunitrazolam             1       1 
Total no. of 
benzodiazepine 
samples  
461 509 682 499 407 357 452 507 570 488 4932 
 
TICTAC Communications Ltd.  
As a provider of drug identification and drug information to the criminal justice and 
healthcare sectors, TICTAC has reported 2 notifications of novel benzodiazepines 
(as of August 2019):  
• 1 sample received from a forensic lab containing norfludiazepam (December 
2017).  
• 1 batch of 32 flualprazolam tablets received from seizures at summer music 
festivals (August 2019). The receipt of batch aligns with a number of 
counterfeit ‘Xanax’ tablets received by TICTAC for testing in the summer of 
2019.   
Welsh Emerging Drug & Identification of Novel Substances (WEDINOS) 
Funded by Public Health Wales, WEDINOS provides laboratory testing of samples 
volunteered by the community. Samples are received anonymously by post from 
either individuals or participating organisations such as substance misuse services, 
housing and hostels, youth clubs and young people’s services, education, night 
clubs and bars, mental health community teams, Local Authorities, the Ambulance 
Service and the Police. Test results are then made publicly available online.  
In the period July to September 2019, benzodiazepines were the most commonly 
identified substances by WEDINOS, with flualprazolam featuring as the 8th most 
common substance identified [WEDINOS, 2019a]. Between October and December 
2019, flualprazolam was the 5th most commonly identified substance [WEDINOS, 
30 
 
2019b]. Over the course of 2019, the presence of flualprazolam in WEDINOS 
samples increased significantly, with identifications almost doubling from 17 in the 
second quarter, to 30 in the third quarter of 2019. As seen with TICTAC sampling, 
most (97%) of these identifications in the third quarter were from samples purchased 
as something else. In many cases, these samples were counterfeit diazepam tablets 
or white ‘Xanax’ bars. This is of concern because of the confirmed potency of this 
compound and its links to deaths across Europe (see flualprazolam section above). 
Including data up to March 2020, no other novel benzodiazepines have been 
identified in community samples received. 
Postscript360  
Postscript360 (previously known as Battle Against Tranquilisers) is a charity based in 
Bristol that provides treatment solutions and referral pathways for people with 
benzodiazepine dependence. They do not keep data concerning substances used by 
their client base, however, in January 2020 they confirmed that clients have 
anecdotally reported either purchasing or using the following substances:  
• Flunitrazolam  
• Norfludiazepam 
• Methyl clonazepam  
• Flualprazolam  
Data on numbers are not available but Postscript360 estimates that 60-70% of their 
clients buy benzodiazepines illicitly via the internet. 
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Annex D: Summary of novel benzodiazepine-related deaths 
in the UK 
The use of the term ‘novel benzodiazepines’ in this section refers to the list of 13 
compounds that the ACMD has considered in this report for control under the MDA. 
National Programme on Substance Abuse Deaths (NPSAD) 
The NPSAD collates information from coroners about deaths related to drugs in 
addicts and non-addicts in England and Wales. To be recorded on the NPSAD 
database, there must be the presence of one or more psychoactive substance(s) 
directly implicated in the death, a history of dependence or abuse of drugs or the 
presence of controlled drugs at post-mortem. NPSAD receives drug related death 
reports from over 80% of its coroners. Cases are recorded by year of death, so 
figures are subject to change as more reports are confirmed.  
NPSAD reported 3 drug-related deaths where flualprazolam was specifically stated 
in the cause of death or implied cause of death due to multiple drug toxicities. A 
further 2 cases were reported where flualprazolam was detected at post mortem, but 
not implicated in the cause of death. No cases associated with the other 12 novel 
benzodiazepines were reported (data up to March 2020). It should be noted that 
further novel benzodiazepine-associated deaths may have occurred, but not 
recorded by NPSAD because of under-reporting and delays to reporting described 
above. Additionally, specific testing needs to be requested by coroners for these 
compounds from toxicology labs and not all toxicology labs are equipped to detect 
these substances. The role of these novel compounds in drug-related deaths may 
therefore be underestimated.  
Northern Ireland Statistics and Research Agency (NISRA) 
In Northern Ireland, there have been 2 flualprazolam-related deaths reported to 
NISRA. In both cases flualprazolam was the cause of death, but toxicity from other 
substances were also identified. There have been no other confirmed cases 
involving the other 12 novel benzodiazepines (data up to March 2020). 
National Records of Scotland (NRS) 
In Scotland, 7 flualprazolam-related deaths had been reported to NRS (data up to 
March 2020). In all 7 cases, the death was not caused by flualprazolam alone: it was 
just one of (usually) several substances implicated in the cause of death, in 
combination. In one additional case, flualprazolam was identified post mortem, but 
was not implicated in the cause of death. NRS has not been informed of any deaths 
involving any of the other 12 novel benzodiazepines. As above it should be noted 
that, due to the time required for toxicology testing and subsequent reporting, further 
novel benzodiazepine-associated deaths may have occurred but have not been 
reported to NRS by March 2020. 
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Annex E: National Poisons Information Service (NPIS) 
telephone enquiries and TOXBASE accesses concerning 
novel benzodiazepines 
 
The NPIS provides the healthcare profession in the UK with information and advice 
on the diagnosis, treatment and management of suspected poisonings in humans. 
Support is provided via the online poisons information database TOXBASE®, or via 
a 24-hour national telephone service. The NPIS can provide information on the 
number of accesses to TOXBASE® and the numbers and details of telephone 
enquiries made to the service by health professionals. These numbers reflect (but do 
not measure directly) the frequency of contacts between health professionals and 
patients presenting following specific suspected exposures. 
In the period April 2014 to March 2019 the NPIS did not receive any telephone 
enquiries in relation to any of the 13 novel benzodiazepines considered in this report.  
As these compounds are novel, many do not have a TOXBASE® page available 
(e.g. flunitrazolam, methyl clonazepam, fluclotizolam, tofisopam, flualprazolam, 
clobromazolam, bentazepam, difludiazepam). Where TOXBASE® pages do exist, 
they have only recently been made available. There have been very few TOXBASE® 
accesses to information about these novel benzodiazepines, except for cinazepam 
and alprazolam triazolobenzophenone derivative. 
Summary of NPIS pages available for novel benzodiazepines, and 
corresponding page accesses from April 2014 to March 2019.  
Novel benzodiazepine 
with TOXBASE page 
available  
  
Date page went 
live 
Number of accesses to page  
2016 2017 2018 2019 
Alprazolam 
triazolobenzophenone 
derivative 
November 2015  5 7 19 37 
Cinazepam May 2016  0 4 73 56 
Cloniprazepam May 2016  0 13 9 2 
Norfludiazepam March 2017 N/A 0 7 7 
Thionordazepam January 2018  N/A N/A 0 4 
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Annex F: List of abbreviations used in this report 
ACMD  Advisory Council on the Misuse of Drugs 
CDC Centers for Disease Control and Prevention 
CND The United Nations Commission on Narcotic Drugs 
DHSC Department of Health and Social Care 
DSTL Defence Science and Technology Laboratory 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EDND European Database on New Drugs 
FEWS Forensic Early Warning System 
GABA gamma-aminobutyric acid 
IONA Identification of Novel Psychoactive Substances  
IUPAC International Union of Pure and Applied Chemistry 
MDA Misuse of Drugs Act 1971 
MDR Misuse of Drugs Regulations 2001 
MHRA  Medicines and Healthcare products Regulatory Agency 
NCA National Crime Agency  
NDTMS National Drug Treatment Monitoring System 
NHSBA National Health Service Business Authority 
NIHR National Institute for Health Research 
NISRA Northern Ireland Statistics and Research Agency 
NPSAD National Programme on Substance Abuse Deaths 
NPIS National Poisons Information Service 
NPS Novel Psychoactive Substances 
NRS National Records of Scotland 
MoJ Ministry of Justice 
ONS Office for National Statistics  
PHE Public Health England  
PSA Psychoactive Substances Act 2016 
TCDO Temporary Class Drug Orders 
UK  United Kingdom 
UNODC United Nations Office on Drugs and Crime 
US  United States  
WEDINOS Welsh Emerging Drug & Identification of Novel Substances 
WHO World Health Organization 
WHO 
ECDD 
World Health Organization’s Expert Committee on Drug 
Dependence 
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Annex G: ACMD membership, at time of publication   
Dr Kostas Agath Consultant Psychiatrist (addictions), CGL 
Southwark 
Professor Owen Bowden-
Jones 
Chair of ACMD, Consultant psychiatrist, Central 
North West London NHS Foundation Trust 
Dr Anne Campbell Senior lecturer in social work and Co-Director of 
the drug and alcohol research network at Queens 
University Belfast 
Mr Mohammed Fessal Chief Pharmacist, CGL 
Dr Emily Finch Clinical Director of the Addictions Clinical 
Academic Group and a consultant psychiatrist for 
South London and Maudsley NHS Trust 
Mr Lawrence Gibbons Head of Drug Threat – NCA Intelligence 
Directorate – Commodities 
Dr Hilary Hamnett Senior Lecturer in Forensic Science, University of 
Lincoln 
Professor Graeme 
Henderson 
Professor of Pharmacology at the University of 
Bristol 
Dr Carole Hunter Lead pharmacist at the alcohol and drug recovery 
services at  
NHS Greater Glasgow and Clyde 
Professor Roger Knaggs Associate professor in clinical pharmacy practice at 
the University of Nottingham 
Professor Tim Millar Professor of Substance Use and Addiction 
Research Strategy Lead at the University of 
Manchester 
Mr Rob Phipps Former Head of Health Development Policy 
Branch, Department of Health, Social Services and 
Public Safety, Northern Ireland 
Mr Harry Shapiro Director – DrugWise 
Dr Richard Stevenson Emergency Medicine Consultant, Glasgow Royal 
Infirmary 
Dr Paul Stokes Senior Clinical Lecturer in mood disorders, King’s 
College, London 
Dr Ann Sullivan Consultant physician in HIV and Sexual health 
Professor Matthew Sutton Chair in Health Economics at the University of 
Manchester and Professorial Research 
Professor David Taylor Professor of Psychopharmacology, King’s College, 
London 
Professor Simon Thomas Consultant physician and clinical pharmacologist, 
Newcastle Hospitals NHS Foundation Trust and 
Professor of Clinical Pharmacology and 
Therapeutics, Newcastle University 
Dr Derek Tracy Consultant Psychiatrist and Clinical Director, 
Oxleas NHS Foundation Trust 
Ms Rosalie Weetman Senior Commissioning Manager of Substance 
Misuse 
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Annex H: ACMD NPS Committee membership, at time of 
publication 
Dr Kostas Agath  Consultant Psychiatrist (addictions), CGL 
Southwark  
Mr Paul Bunt Director of Casterton Event Solutions Ltd, Former 
Drug Strategy Manager for Avon and Somerset 
Constabulary  
Dr Anne Campbell  
 
Senior lecturer in social work and Co-Director of 
the drug and alcohol research network at Queens 
University Belfast 
Mr John Corkery  Senior Lecturer in Pharmacy Practice at University 
of Hertfordshire 
Mr Lawrence Gibbons  Head of Drug Threat – NCA Intelligence 
Directorate – Commodities  
Dr Hilary Hamnett  Senior Lecturer in Forensic Science, University of 
Lincoln  
Professor Graeme 
Henderson  
Professor of Pharmacology at the University of 
Bristol  
Professor Roger Knaggs   Associate professor in clinical pharmacy practice 
at the University of Nottingham  
Professor Fiona 
Measham 
Professor and chair in criminology, University of 
Liverpool; co-founder and co-director, the Loop 
Mr Harry Shapiro Director - DrugWise  
Dr Richard Stevenson  Emergency Medicine Consultant, Glasgow Royal 
Infirmary  
Dr Ann Sullivan  Consultant physician in HIV and Sexual health 
Professor Simon Thomas  NPS Committee Chair, Consultant physician and 
clinical pharmacologist, Newcastle Hospitals NHS 
Foundation Trust and Professor of Clinical 
Pharmacology and Therapeutics, Newcastle 
University 
Mr Ric Treble  Retired Laboratory of the Government Chemist 
(LGC) expert 
Dr Mike White  Former Forensic Intelligence Adviser  
Dr David Wood  Consultant physician and clinical toxicologist at 
Guy's and St Thomas' and reader in clinical 
toxicology at King’s College London 
 
In addition to members of the NPS committee listed, significant contributions were 
made by NPSAD and the NPIS and a special mention would like to be extended to 
both organisations. 
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Annex I: Quality of evidence  
Range of Evidence  
Evidence gathered was considered in line with the ACMD’s ‘Standard Operating 
Procedure (SOP) for using evidence in ACMD reports’ [ACMD, 2020]. 
Evidence relating to the identification and prevalence of the 13 novel 
benzodiazepines in Europe was taken from the EMCDDA’s EDND. Each time a new 
drug is identified by a participating country in Europe, the EMCDDA produces a 
formal notification document, which details structural, chemical and pharmacological 
information of the substance if available and then set up a page on the EDND. The 
database then records any further substance notifications in Europe or reports of 
adverse effects.   
To evidence the identification and prevalence of novel benzodiazepines in the UK, 
the ACMD’s NPS Committee wrote to stakeholders requesting available data on the 
13 substances. Responses were received from the following (which include 
submissions of ‘no data held’ and anecdotal evidence: 
External agencies: 
• NCA 
• NISRA  
• NPSAD  
• NPIS  
• NRS  
• National Drug Treatment Monitoring System (NDTMS) 
• Postscript360  
• TICTAC Communications Ltd  
• WEDINOS  
Government Departments: 
• Border Force Intelligence Analysis (Home Office) 
• FEWS (DSTL) 
• MHRA  
• Ministry of Justice (MoJ)  
• UK Focal Point (PHE) 
This report also draws on evidence from peer-reviewed literature (UK and 
international publications) and government reports. The ACMD also considered 
international approaches when drafting its recommendations. 
Quality of evidence (design, limitations, bias) 
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For 3 of the 13 novel benzodiazepines considered in this report, there was strong 
evidence of their availability and harm - allowing the ACMD to make an informed 
recommendation on their classification and schedule.   
Many agencies and departments returned ‘no data held’ for most of the novel 
benzodiazepines in this report. It is important to note that owing to the ‘novelty’ of all 
of these substances, forensic testing is limited and inconsistent across the UK and 
as a result, information being fed into reporting agencies that were approached will 
not be representative. This is proven by anecdotal data provided by benzodiazepine 
dependence treatment provider, Postscript360, which reported clients either 
purchasing or using methyl clonazepam, despite there being no forensic evidence 
available of methyl clonazepam in the UK. As reports have identified these 
substances elsewhere in Europe, there is potential availability of these substances in 
the UK, however, this connection is too weak to deduce a classification under the 
MDA.  
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